Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blossom: Obinutuzumab vs Cyclophosphamide in Primary Membranous Nephropathy
NCT06781944Phase 3Recruiting
- Sponsor
- Huashan Hospital
- Start
- Oct 2024
- Primary completion
- May 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of obinutuzumab in primary membranous nephropathy (PMN), sponsored by Huashan Hospital. Started Oct 2024; status: recruiting.
02
Drugs
obinutuzumab
03
Conditions
primary membranous nephropathy (PMN)
Beyond the preview
Go deeper on NCT06781944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06781944.